[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-356259-105":59,"doc-detail-356259-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","broad-utility-of-ultrasensitive-analysis-of-ctdna-dynamics-across-solid-tumors-treated-with-immunotherapy","Broad Utility of Ultrasensitive Analysis of ctDNA Dynamics across Solid Tumors Treated with Immunotherapy","","Plasma-derived ctDNA has been explored as a biomarker for cancers treated with immune checkpoint inhibitors, but its clinical value across tumor types and immunotherapy strategies remains to be fully defined. This study assesses whether ultrasensitive ctDNA detection can predict progression-free and overall survival, using tumor whole-genome sequencing–informed analyses in a retrospective and prospective cohort. Molecular response measured early and ctDNA clearance are linked to survival and imaging response, while dynamics distinguish true progression from pseudoprogression.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/broad-utility-of-ultrasensitive-analysis-of-ctdna-dynamics-across-solid-tumors-treated-with-immunotherapy/356259/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/broad-utility-of-ultrasensitive-analysis-of-ctdna-dynamics-across-solid-tumors-treated-with-immunotherapy/356259.png","ImageObject",300,407,{"name":92,"@type":93},"Patrick","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-10-27","2026-09-23",true,{"@type":102,"interactionType":103,"userInteractionCount":29},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"What was the study’s primary goal regarding ctDNA and immunotherapy?","Question",{"text":112,"@type":113},"To evaluate whether ultrasensitive ctDNA detection can predict progression-free and overall survival in advanced cancer patients receiving immune checkpoint inhibitors.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"How were ultrasensitive ctDNA analyses performed in this research?",{"text":117,"@type":113},"Tumor whole-genome sequencing–informed, ultrasensitive ctDNA analysis tracked about 1,800 tumor-specific mutations per patient across a retrospective and prospective cohort.",{"name":119,"@type":110,"acceptedAnswer":120},"What did the study find about ctDNA response and ctDNA clearance?",{"text":121,"@type":113},"Early ctDNA molecular response (as soon as 3 weeks) correlated with improved progression-free and overall survival, and ctDNA clearance correlated strongly with radiologic response and prolonged survival.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},356259,1790665950,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":29,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":139,"language":140,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":67,"update_tm":144,"read_time":145,"preview_page_count":19,"preview_urls":146},549758146520,"https://ap-avatar.wpscdn.com/avatar/80002397d8c0411e94?_k=1775819394049821470","Broad Utility of Ultrasensitive Analysis of ctDNA Dynamics across Solid Tumors Treated with Immunotherapy  \nElena Garralda1, Charles Abbott2, Alma Calahorro1, Oriol Mirallas1, Jason Pugh2, Ana Beln Moreno-Crdenas1, Kathleen Keough2, Vladimir Galvao1, Guzman Alonso1, Armando Mel Olano1, Mara Vieito Villar1, Arjun Oberoi1, Julia Lostes Bardaji1, Alberto Hernando-Calvo1, Irene Braña1, Giulia Pretelli1, Belen Ortega1, Carlota Arenillas1, Natalia Czerniak1, Fbio C. P. Navarro2, Bailiang Li2, Rachel Marty Pyke2, Neeraja Ravi2,  \nChristina Zatse1, Francesco Grussu1, Marta Sanz1, Cristina Viaplana1, Kira Raskina1, Jose Jimenez1, Roberta Fasani1, Patricia Casbas-Hernandez3, Ezoglin Oflazoglu3, Darren Hodgson4,  \nJorge Reis-Filho3, Enriqueta Felip1, Elena ´Elez1, Eva Muñoz1, Rodrigo Dienstmann1, Josep Tabernero1, Raquel Lopez-Perez1, Paolo Nuciforo1, Richard O. Chen2, Sean M. Boyle2, and Rodrigo A. Toledo1  \n|  |  | A |  | B | S |  | T | R |  | A |  | C | T |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |\n| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |\n|  | Purpose: Prior studies have suggested the biomarker potential of plasma-derived ctDNA in patients with cancer treated with immune checkpoint inhibitors. This study investigated the ability of ctDNA to predict progression-free and overall survival in a cohort of patients with advanced cancer treated with immunotherapies.\u003Cbr>Experimental Design: In order to characterize the potential role of ultrasensitive ctDNA detection in the management of these patients, we have performed tumor whole-genome sequencing– informed, ultrasensitive ctDNA analysis—tracking approximately 1,800 tumor-specific mutations per patient—in a retrospective cohort (n ¼ 136) and a prospective validation cohort (n ¼ 66) across 24 cancer types treated with immune checkpoint inhibitors\u003Cbr>􀀶 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | alone or in combination with bispecific antibodies or immune cell engagers.\u003Cbr>Results: Analyzing 1,455 longitudinal samples, we found that ctDNA molecular response measured as early as 3 weeks after treatment initiation correlated with improved progression-free and overall survival, whereas ctDNA clearance at any time strongly correlated with radiologic response and prolonged survival. Additionally, ctDNA dynamics distinguished true progression from pseudoprogression and predicted outcomes in patients receiving continued immunotherapy beyond initial progression.\u003Cbr>Conclusions: This study highlights the broader applicability of ultrasensitive ctDNA as a biomarker across cancer types and immunotherapy modalities. |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |\n\nIntroduction  \nCancer immunotherapy has revolutionized oncology by leveraging the patient’s immune system to recognize and eliminate tumor cells. The approval of the first immune checkpoint inhibitor (ICI) in 2011 for metastatic melanoma marked a paradigm shift in cancer treatment, leading to the development of antibodies targeting key immune checkpoints, including CTLA-4, PD-1, PD-","cbCaikJVtEhjgYO9","https://ap.wps.com/l/cbCaikJVtEhjgYO9","pdf",6162496,17,"English","# Purpose\n## Experimental Design\n## Results\n## Conclusions\n# Introduction","[{\"question\":\"What was the study’s primary goal regarding ctDNA and immunotherapy?\",\"answer\":\"To evaluate whether ultrasensitive ctDNA detection can predict progression-free and overall survival in advanced cancer patients receiving immune checkpoint inhibitors.\"},{\"question\":\"How were ultrasensitive ctDNA analyses performed in this research?\",\"answer\":\"Tumor whole-genome sequencing–informed, ultrasensitive ctDNA analysis tracked about 1,800 tumor-specific mutations per patient across a retrospective and prospective cohort.\"},{\"question\":\"What did the study find about ctDNA response and ctDNA clearance?\",\"answer\":\"Early ctDNA molecular response (as soon as 3 weeks) correlated with improved progression-free and overall survival, and ctDNA clearance correlated strongly with radiologic response and prolonged survival.\"}]","Broad Utility of Ultrasensitive Analysis of ctDNA Dynamics across Solid Tumors Treated with Immunotherapy | PDF",1790124276,43,[147,151,155,159],{"page_no":8,"url":148,"width":149,"height":150},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/819a1233293e8386351e1de00b755d40.webp",983,1315,{"page_no":14,"url":152,"width":153,"height":154},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/7d4e0f0d8ea31ed0dae8b6f91979f88f.webp",982,1314,{"page_no":81,"url":156,"width":157,"height":158},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/ca2c8d6fa9971de9b617128227060638.webp",981,1312,{"page_no":19,"url":160,"width":161,"height":162},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/cab17dfd7cc3c39b7404fbca0bbe7db6.webp",980,1311]